Trial Outcomes & Findings for Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis (NCT NCT02743871)

Last Updated: 2022-05-19

Results Overview

An adverse event (AE) was any untoward medical occurrence in a clinical investigation where participants administered a product or medical device; the event needed not necessarily have a causal relationship with the treatment or usage. TEAEs were events between first dose of study drug and up to discharge from study that were absent before treatment or that worsened relative to pretreatment state. An SAE was any untoward medical occurrence at any dose that: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or results in congenital anomaly/birth defect.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

97 participants

Primary outcome timeframe

From Study Day 1 (baseline) up to Day 421 (Cohort 1 and 2), Day 601 (Cohort 3), Day 691 (Cohort 4), Day 781 (Cohort 5), and Day 511 (Cohort 7).

Results posted on

2022-05-19

Participant Flow

A total of 97 participants were assigned and treated in this study, with 49, 20, and 28 participants in Part 1, 2, and 3, respectively.

Participant milestones

Participant milestones
Measure	Part 1 Cohort 1: PF-06817024 10 mg Intravenously (IV) Single Dose (SD) Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 7: PF-06817024 30 mg Subcutaneously (SC) SD Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV Multiple Doses (MD) Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.	Part 2 Cohort 8: PF-06817024 300 mg IV Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Participants with chronic rhinosinusitis with nasal polyps (CRSwNP) received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 2 Cohort 8: Placebo IV CRSwNP Participants with CRSwNP received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 3 Cohort 13: PF-06817024 600 mg => 300 mg IV Atopic Dermatitis (AD) Participants with moderate to severe AD received PF-06817024 600 mg loading dose IV on Study Day 1 followed by 3 doses of PF-06817024 300 mg IV on Study Days 29, 57, and 85.	Part 3 Cohort 13: Placebo IV AD Participants with moderate to severe AD received the matching placebo of PF-06817024 IV on Study Days 1, 29, 57, and 85.
Overall Study STARTED	6	6	6	3	4	6	6	8	2	2	11	9	20	8
Overall Study COMPLETED	5	6	6	2	4	6	5	8	2	2	10	6	5	1
Overall Study NOT COMPLETED	1	0	0	1	0	0	1	0	0	0	1	3	15	7

Reasons for withdrawal

Reasons for withdrawal
Measure	Part 1 Cohort 1: PF-06817024 10 mg Intravenously (IV) Single Dose (SD) Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 2 Cohort 8: PF-06817024 300 mg IV Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Participants with chronic rhinosinusitis with nasal polyps (CRSwNP) received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 2 Cohort 8: Placebo IV CRSwNP Participants with CRSwNP received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 3 Cohort 13: PF-06817024 600 mg => 300 mg IV Atopic Dermatitis (AD) Participants with moderate to severe AD received PF-06817024 600 mg loading dose IV on Study Day 1 followed by 3 doses of PF-06817024 300 mg IV on Study Days 29, 57, and 85.	Part 3 Cohort 13: Placebo IV AD Participants with moderate to severe AD received the matching placebo of PF-06817024 IV on Study Days 1, 29, 57, and 85.
Overall Study Lost to Follow-up	0	1	1	0	2	0	0
Overall Study Withdrawal by Subject	0	0	0	1	0	12	6
Overall Study Adverse Event	1	0	0	0	0	0	0
Overall Study Other	0	0	0	0	1	1	1
Overall Study Protocol Violation	0	0	0	0	0	2	0

Baseline Characteristics

Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Part 1 Cohort 1: PF-06817024 10 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 7: PF-06817024 30 mg SC SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD n=3 Participants Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV MD n=4 Participants Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD n=8 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD n=2 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD n=2 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.	Part 2 Cohort 8: PF-06817024 300 mg IV CRSwNP n=11 Participants Participants with CRSwNP received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 2 Cohort 8: Placebo IV CRSwNP n=9 Participants Participants with CRSwNP received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 3 Cohort 13: PF-06817024 600 mg => 300 mg IV AD n=20 Participants Participants with moderate to severe AD received PF-06817024 600 mg loading dose IV on Study Day 1 followed by 3 doses of PF-06817024 300 mg IV on Study Days 29, 57, and 85.	Part 3 Cohort 13: Placebo IV AD n=8 Participants Participants with moderate to severe AD received the matching placebo of PF-06817024 IV on Study Days 1, 29, 57, and 85.	Total n=97 Participants Total of all reporting groups
Age, Continuous	34.0 years STANDARD_DEVIATION 4.9 • n=5 Participants	37.0 years STANDARD_DEVIATION 10.7 • n=7 Participants	43.2 years STANDARD_DEVIATION 8.7 • n=5 Participants	27.0 years STANDARD_DEVIATION 6.1 • n=4 Participants	26.5 years STANDARD_DEVIATION 6.8 • n=21 Participants	36.3 years STANDARD_DEVIATION 7.7 • n=8 Participants	39.8 years STANDARD_DEVIATION 8.7 • n=8 Participants	33.3 years STANDARD_DEVIATION 12.0 • n=24 Participants	23.5 years STANDARD_DEVIATION 0.7 • n=42 Participants	34.5 years STANDARD_DEVIATION 4.9 • n=42 Participants	54.4 years STANDARD_DEVIATION 6.2 • n=42 Participants	42.8 years STANDARD_DEVIATION 10.7 • n=42 Participants	38.9 years STANDARD_DEVIATION 13.8 • n=36 Participants	41.0 years STANDARD_DEVIATION 17.4 • n=36 Participants	49.2 years STANDARD_DEVIATION 10.2 • n=24 Participants
Sex: Female, Male Female	0 Participants n=5 Participants	0 Participants n=7 Participants	2 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	1 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	3 Participants n=42 Participants	4 Participants n=42 Participants	12 Participants n=36 Participants	7 Participants n=36 Participants	29 Participants n=24 Participants
Sex: Female, Male Male	6 Participants n=5 Participants	6 Participants n=7 Participants	4 Participants n=5 Participants	3 Participants n=4 Participants	4 Participants n=21 Participants	6 Participants n=8 Participants	6 Participants n=8 Participants	7 Participants n=24 Participants	2 Participants n=42 Participants	2 Participants n=42 Participants	8 Participants n=42 Participants	5 Participants n=42 Participants	8 Participants n=36 Participants	1 Participants n=36 Participants	68 Participants n=24 Participants
Race/Ethnicity, Customized White	1 Participants n=5 Participants	3 Participants n=7 Participants	3 Participants n=5 Participants	1 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=8 Participants	1 Participants n=8 Participants	3 Participants n=24 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants	11 Participants n=42 Participants	7 Participants n=42 Participants	8 Participants n=36 Participants	3 Participants n=36 Participants	44 Participants n=24 Participants
Race/Ethnicity, Customized Black	4 Participants n=5 Participants	2 Participants n=7 Participants	2 Participants n=5 Participants	2 Participants n=4 Participants	1 Participants n=21 Participants	4 Participants n=8 Participants	3 Participants n=8 Participants	3 Participants n=24 Participants	2 Participants n=42 Participants	1 Participants n=42 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants	9 Participants n=36 Participants	3 Participants n=36 Participants	37 Participants n=24 Participants
Race/Ethnicity, Customized Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	1 Participants n=8 Participants	1 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants	1 Participants n=36 Participants	0 Participants n=36 Participants	4 Participants n=24 Participants
Race/Ethnicity, Customized Other	1 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	2 Participants n=21 Participants	1 Participants n=8 Participants	1 Participants n=8 Participants	1 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	2 Participants n=36 Participants	2 Participants n=36 Participants	12 Participants n=24 Participants

PRIMARY outcome

Timeframe: From Study Day 1 (baseline) up to Day 421 (Cohort 1 and 2), Day 601 (Cohort 3), Day 691 (Cohort 4), Day 781 (Cohort 5), and Day 511 (Cohort 7).

Population: All participants who received at least 1 dose of study medication.

Outcome measures

Outcome measures
Measure	Part 1 Cohort 1: PF-06817024 10 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 30 mg SC SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD n=3 Participants Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV MD n=4 Participants Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD n=8 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD n=2 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD n=2 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.
Number of Participants With All-causality Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Part 1 Number of Participants With All-Causality SAEs	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With All-causality Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Part 1 Number of Participants With All-Causality TEAEs	6 Participants	4 Participants	5 Participants	3 Participants	1 Participants	6 Participants	4 Participants	8 Participants	2 Participants	2 Participants

PRIMARY outcome

Timeframe: From Study Day 1 (baseline) up to Day 421 (Cohort 1 and 2), Day 601 (Cohort 3), Day 691 (Cohort 4), Day 781 (Cohort 5), and Day 511 (Cohort 7).

Population: All participants who received at least 1 dose of study medication.

An AE was any untoward medical occurrence in a clinical investigation where participants administered a product or medical device; the event needed not necessarily have a causal relationship with the treatment or usage. TEAEs were events between first dose of study drug and up to discharge from study that were absent before treatment or that worsened relative to pretreatment state. An SAE was any untoward medical occurrence at any dose that: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or results in congenital anomaly/birth defect. The causality of TEAEs and SAEs was determined by the investigator.

Outcome measures

Outcome measures
Measure	Part 1 Cohort 1: PF-06817024 10 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 30 mg SC SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD n=3 Participants Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV MD n=4 Participants Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD n=8 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD n=2 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD n=2 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.
Number of Participants With Treatment-Related TEAEs and SAEs in Part 1 Number of Participants With Treatment-Related TEAEs	2 Participants	2 Participants	2 Participants	2 Participants	1 Participants	3 Participants	1 Participants	1 Participants	0 Participants	1 Participants
Number of Participants With Treatment-Related TEAEs and SAEs in Part 1 Number of Participants With Treatment-Related SAEs	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: From Study Day 1 (baseline) up to Day 421 (Cohort 1 and 2), Day 601 (Cohort 3), Day 691 (Cohort 4), Day 781 (Cohort 5), and Day 511 (Cohort 7).

Population: All participants who received at least 1 dose of study medication.

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were events between first dose of study drug and up to discharge from study that were absent before treatment or that worsened relative to pretreatment state. TEAE was assessed by the investigator according to severity; Mild: did not interfere with participant's usual function; moderate: interfered to some extent with participant's usual function; severe: interfered significantly with participant's usual function.

Outcome measures

Outcome measures
Measure	Part 1 Cohort 1: PF-06817024 10 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 30 mg SC SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD n=3 Participants Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV MD n=4 Participants Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD n=8 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD n=2 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD n=2 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.
Number of All-Causality TEAEs According to Severity in Part 1 Mild	14 Events	10 Events	20 Events	11 Events	4 Events	15 Events	10 Events	30 Events	3 Events	4 Events
Number of All-Causality TEAEs According to Severity in Part 1 Moderate	2 Events	2 Events	1 Events	0 Events	0 Events	2 Events	1 Events	2 Events	0 Events	0 Events
Number of All-Causality TEAEs According to Severity in Part 1 Severe	0 Events	0 Events	0 Events	0 Events	0 Events	0 Events	0 Events	0 Events	0 Events	0 Events

PRIMARY outcome

Timeframe: From Study Day 1 (baseline) up to Day 421 (Cohort 1 and 2), Day 601 (Cohort 3), Day 691 (Cohort 4), Day 781 (Cohort 5), and Day 511 (Cohort 7).

Population: All participants who received at least 1 dose of study medication.

Outcome measures

Outcome measures
Measure	Part 1 Cohort 1: PF-06817024 10 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 30 mg SC SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD n=3 Participants Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV MD n=4 Participants Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD n=8 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD n=2 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD n=2 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.
Number of Participants With Permanent Discontinuation Due to TEAEs in Part 1	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: From Study Day 1 (baseline) up to Day 691.

Population: All participants who received at least 1 dose of study medication.

Outcome measures

Outcome measures
Measure	Part 1 Cohort 1: PF-06817024 10 mg IV SD n=11 Participants Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD n=9 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 30 mg SC SD Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV MD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.
Number of Participants With All-Causality TEAEs and SAEs in Part 2 Number of Participants With All-Causality TEAEs	10 Participants	8 Participants	—	—	—	—	—	—	—	—
Number of Participants With All-Causality TEAEs and SAEs in Part 2 Number of Participants With All-Causality SAEs	0 Participants	1 Participants	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: From Study Day 1 (baseline) up to Day 691.

Population: All participants who received at least 1 dose of study medication.

Outcome measures

Outcome measures
Measure	Part 1 Cohort 1: PF-06817024 10 mg IV SD n=11 Participants Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD n=9 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 30 mg SC SD Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV MD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.
Number of Participants With Treatment-Related TEAEs and SAEs in Part 2 Number of Participants With Treatment-Related TEAEs	5 Participants	3 Participants	—	—	—	—	—	—	—	—
Number of Participants With Treatment-Related TEAEs and SAEs in Part 2 Number of Participants With Treatment-Related SAEs	0 Participants	0 Participants	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: From Study Day 1 (baseline) up to Day 691.

Population: All participants who received at least 1 dose of study medication.

Outcome measures

Outcome measures
Measure	Part 1 Cohort 1: PF-06817024 10 mg IV SD n=11 Participants Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD n=9 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 30 mg SC SD Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV MD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.
Number of All-Causality TEAEs According to Severity in Part 2 Mild	44 Events	24 Events	—	—	—	—	—	—	—	—
Number of All-Causality TEAEs According to Severity in Part 2 Moderate	14 Events	9 Events	—	—	—	—	—	—	—	—
Number of All-Causality TEAEs According to Severity in Part 2 Severe	0 Events	3 Events	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: From Study Day 1 (baseline) up to Day 691.

Population: All participants who received at least 1 dose of study medication.

Outcome measures

Outcome measures
Measure	Part 1 Cohort 1: PF-06817024 10 mg IV SD n=11 Participants Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD n=9 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 30 mg SC SD Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV MD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.
Number of Participants With Permanent Discontinuation Due to TEAEs in Part 2	0 Participants	0 Participants	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: From Study Day 1 (baseline) up to Day 1105.

Population: All participants who received at least 1 dose of study medication.

Outcome measures

Outcome measures
Measure	Part 1 Cohort 1: PF-06817024 10 mg IV SD n=20 Participants Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD n=8 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 30 mg SC SD Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV MD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.
Number of Participants With All-Causality TEAEs and SAEs in Part 3 Number of Participants With All-Causality TEAEs	12 Participants	5 Participants	—	—	—	—	—	—	—	—
Number of Participants With All-Causality TEAEs and SAEs in Part 3 Number of Participants With All-Causality SAEs	3 Participants	1 Participants	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: From Study Day 1 (baseline) up to Day 1105.

Population: All participants who received at least 1 dose of study medication.

Outcome measures

Outcome measures
Measure	Part 1 Cohort 1: PF-06817024 10 mg IV SD n=20 Participants Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD n=8 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 30 mg SC SD Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV MD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.
Number of Participants With Treatment-Related TEAEs and SAEs in Part 3 Number of Participants With Treatment-Related TEAEs	5 Participants	0 Participants	—	—	—	—	—	—	—	—
Number of Participants With Treatment-Related TEAEs and SAEs in Part 3 Number of Participants With Treatment-Related SAEs	1 Participants	0 Participants	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: From Study Day 1 (baseline) up to Day 1105.

Population: All participants who received at least 1 dose of study medication.

Outcome measures

Outcome measures
Measure	Part 1 Cohort 1: PF-06817024 10 mg IV SD n=20 Participants Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD n=8 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 30 mg SC SD Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV MD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.
Number of All-Causality TEAEs According to Severity in Part 3 Severe	13 TEAEs	1 TEAEs	—	—	—	—	—	—	—	—
Number of All-Causality TEAEs According to Severity in Part 3 Mild	12 TEAEs	2 TEAEs	—	—	—	—	—	—	—	—
Number of All-Causality TEAEs According to Severity in Part 3 Moderate	15 TEAEs	5 TEAEs	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: From Study Day 1 (baseline) up to Day 1105.

Population: All participants who received at least 1 dose of study medication.

An AE was any untoward medical occurrence in a clinical investigation participants administered a product or medical device; the event needed not necessarily have a causal relationship with the treatment or usage. TEAEs were events between first dose of study drug and up to discharge from study that were absent before treatment or that worsened relative to pretreatment state.

Outcome measures

Outcome measures
Measure	Part 1 Cohort 1: PF-06817024 10 mg IV SD n=20 Participants Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD n=8 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 30 mg SC SD Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV MD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.
Number of Participants With Permanent Discontinuation Due to TEAEs in Part 3	0 Participants	0 Participants	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Part 1 single-dose cohorts: from Study Day 1 (baseline) up to Day 211. Part 1 multiple-dose cohorts: from Study Day 1 (baseline) up to Day 241.

Population: All participants who received at least 1 dose of study medication.

Hematology parameters included hemoglobin, hematocrit, red blood cell, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet and white blood cell count, total neutrophils, eosinophils, monocytes, basophils and lymphocytes. Chemistry parameters included blood urea nitrogen, glucose (fasting), calcium, sodium, potassium, chloride, bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein. Urine parameters included pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, urobilinogen, urine bilirubin, microscopy. Clinical significance was judged by the investigator and those met the criteria of AE are listed here. Clinically significant laboratory abnormalities reported for at least 1 participant in the whole study are presented here.

Outcome measures

Outcome measures
Measure	Part 1 Cohort 1: PF-06817024 10 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 30 mg SC SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD n=3 Participants Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV MD n=4 Participants Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD n=8 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD n=2 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD n=2 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.
Number of Participants With Clinically Significant Laboratory Abnormalities in Hematology, Chemistry, and Urinalysis in Part 1 Blood creatine phosphokinase increased	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities in Hematology, Chemistry, and Urinalysis in Part 1 Transaminases increased	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants

PRIMARY outcome

Timeframe: Part 2: from Study Day 1 (baseline) up to Day 211.

Population: All participants who received at least 1 dose of study medication.

Outcome measures

Outcome measures
Measure	Part 1 Cohort 1: PF-06817024 10 mg IV SD n=11 Participants Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD n=9 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 30 mg SC SD Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV MD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.
Number of Participants With Clinically Significant Laboratory Abnormalities in Hematology, Chemistry, and Urinalysis in Part 2 Transaminases increased	0 Participants	0 Participants	—	—	—	—	—	—	—	—
Number of Participants With Clinically Significant Laboratory Abnormalities in Hematology, Chemistry, and Urinalysis in Part 2 Blood creatine phosphokinase increased	0 Participants	0 Participants	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Part 3: from Study Day 1 (baseline) up to Day 966.

Population: All participants who received at least 1 dose of study medication.

Outcome measures

Outcome measures
Measure	Part 1 Cohort 1: PF-06817024 10 mg IV SD n=20 Participants Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD n=8 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 30 mg SC SD Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV MD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.
Number of Participants With Clinically Significant Laboratory Abnormalities in Hematology, Chemistry, and Urinalysis in Part 3 Transaminases increased	1 Participants	0 Participants	—	—	—	—	—	—	—	—
Number of Participants With Clinically Significant Laboratory Abnormalities in Hematology, Chemistry, and Urinalysis in Part 3 Blood creatine phosphokinase increased	0 Participants	0 Participants	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Study Day 1 (baseline) up to end of study (Study Day 211 for Part 1 SD cohorts, and Study Day 241 for Part 1 MD cohorts).

Population: All participants who received at least 1 dose of study medication.

Criteria for abnormality in vital signs: supine pulse rate \<40 beats per minute (bpm) or \>120 bpm; supine diastolic blood pressure (DBP) \<50 mmHg, maximum increase or decrease from baseline of \>=20 mmHg; supine systolic blood pressure (SBP) \<90 mmHg, maximum increase or decrease from baseline of \>=30 mmHg. Baseline was defined as the last measurement prior to the first dosing. Vital sign abnormalities reported for at least 1 participant are presented here.

Outcome measures

Outcome measures
Measure	Part 1 Cohort 1: PF-06817024 10 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 30 mg SC SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD n=3 Participants Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV MD n=4 Participants Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD n=8 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD n=2 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD n=2 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.
Number of Participants With Vital Sign Abnormalities in Part 1 Maximum Increase from Baseline in Supine SBP >= 30 mmHg	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	2 Participants	0 Participants	0 Participants
Number of Participants With Vital Sign Abnormalities in Part 1 Maximum Decrease from Baseline in Supine DBP >= 20 mmHg	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants
Number of Participants With Vital Sign Abnormalities in Part 1 Supine SBP <90 mmHg	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants	0 Participants	1 Participants
Number of Participants With Vital Sign Abnormalities in Part 1 Supine DBP <50 mmHg	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants
Number of Participants With Vital Sign Abnormalities in Part 1 Maximum Increase from Baseline in Supine DBP >= 20 mmHg	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Vital Sign Abnormalities in Part 1 Maximum Decrease from Baseline in Supine SBP >= 30 mmHg	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: Study Day 1 (baseline) up to end of study (Study Day 211).

Population: All participants who received at least 1 dose of study medication.

Criteria for abnormality in vital signs: supine pulse rate \<40 bpm or \>120 bpm; supine DBP \<50 mmHg, maximum increase or decrease from baseline of \>=20 mmHg; supine SBP \<90 mmHg, maximum increase or decrease from baseline of \>=30 mmHg. Baseline was defined as the last measurement prior to the first dosing. Vital sign abnormalities reported for at least 1 participant are presented here.

Outcome measures

Outcome measures
Measure	Part 1 Cohort 1: PF-06817024 10 mg IV SD n=11 Participants Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD n=9 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 30 mg SC SD Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV MD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.
Number of Participants With Vital Sign Abnormalities in Part 2 Supine SBP <90 mmHg	1 Participants	0 Participants	—	—	—	—	—	—	—	—
Number of Participants With Vital Sign Abnormalities in Part 2 Maximum Increase from Baseline in Supine SBP >= 30 mmHg	1 Participants	0 Participants	—	—	—	—	—	—	—	—
Number of Participants With Vital Sign Abnormalities in Part 2 Maximum Decrease from Baseline in Supine SBP >= 30 mmHg	2 Participants	0 Participants	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Study Day 1 (baseline) up to end of study (Study Day 337).

Population: All participants who received at least 1 dose of study medication.

Outcome measures

Outcome measures
Measure	Part 1 Cohort 1: PF-06817024 10 mg IV SD n=20 Participants Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD n=8 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 30 mg SC SD Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV MD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.
Number of Participants With Vital Sign Abnormalities in Part 3 Maximum Increase from Baseline in Supine SBP >= 30 mmHg	1 Participants	0 Participants	—	—	—	—	—	—	—	—
Number of Participants With Vital Sign Abnormalities in Part 3 Maximum Increase from Baseline in Supine DBP >= 20 mmHg	3 Participants	0 Participants	—	—	—	—	—	—	—	—
Number of Participants With Vital Sign Abnormalities in Part 3 Supine DBP <50 mmHg	1 Participants	0 Participants	—	—	—	—	—	—	—	—
Number of Participants With Vital Sign Abnormalities in Part 3 Maximum Decrease from Baseline in Supine DBP >= 20 mmHg	2 Participants	0 Participants	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Study Day 1 (baseline) up to end of study (Study Day 211 for Part 1 SD cohorts, and Study Day 241 for Part 1 MD cohorts).

Population: All participants who received at least 1 dose of study medication.

ECG abnormalities criteria included: 1) maximum QTc interval adjusted according Fridericia formula (QTcF) (msec): 450\<= QTcF \<480, 480\<= QTcF \<500, and QTcF \>=500; QTcF maximum increase from baseline(msec): 30\<= change \<60, and change \>=60; 2) maximum PR interval (msec): \>=300; PR increase from baseline (msec): baseline \>200 with 25% increase at maximum, baseline \<=200 with 50% increase at maximum; 3) maximum QRS (msec): \>=140; QRS increase from baseline (msec) \>=50%. Baseline was defined as the average of the last triplicate measurement prior to the first dosing. ECG abnormalities reported for at least 1 participant are presented here.

Outcome measures

Outcome measures
Measure	Part 1 Cohort 1: PF-06817024 10 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 30 mg SC SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD n=3 Participants Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV MD n=4 Participants Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD n=8 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD n=2 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD n=2 Participants Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.
Number of Participants With Electrocardiogram (ECG) Abnormalities in Part 1 450 <= maximum QTcF interval (msec) <480	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	2 Participants	0 Participants	0 Participants
Number of Participants With Electrocardiogram (ECG) Abnormalities in Part 1 30 <= maximum QTcF interval increase from baseline (msec) <60	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	2 Participants	1 Participants	0 Participants

PRIMARY outcome

Timeframe: Study Day 1 (baseline) up to end of study (Study Day 211).

Population: All participants who received at least 1 dose of study medication.

Outcome measures

Outcome measures
Measure	Part 1 Cohort 1: PF-06817024 10 mg IV SD n=11 Participants Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD n=9 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 30 mg SC SD Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV MD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.
Number of Participants With ECG Abnormalities in Part 2 450 <= maximum QTcF interval (msec) <480	1 Participants	2 Participants	—	—	—	—	—	—	—	—
Number of Participants With ECG Abnormalities in Part 2 30 <= maximum QTcF interval increase from baseline (msec) <60	1 Participants	1 Participants	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Study Day 1 (baseline) up to end of study (Study Day 337).

Population: All participants who received at least 1 dose of study medication.

Outcome measures

Outcome measures
Measure	Part 1 Cohort 1: PF-06817024 10 mg IV SD n=20 Participants Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD n=8 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 30 mg SC SD Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV MD Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.
Number of Participants With ECG Abnormalities in Part 3 450 <= maximum QTcF interval (msec) <480	2 Participants	2 Participants	—	—	—	—	—	—	—	—
Number of Participants With ECG Abnormalities in Part 3 30 <= maximum QTcF interval increase from baseline (msec) <60	5 Participants	2 Participants	—	—	—	—	—	—	—	—
Number of Participants With ECG Abnormalities in Part 3 Maximum QTcF interval increase from baseline (msec) >=60	1 Participants	0 Participants	—	—	—	—	—	—	—	—
Number of Participants With ECG Abnormalities in Part 3 Maximum QTcF interval (msec) >=500	0 Participants	1 Participants	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 1, 2, 4, 8, 12, 24, 48, 72, 96 hours post dose on Day 1, and on Follow-up Days 8, 15, 32, 46, 61, 91, 121, 151, 181, 211, and at Extended Follow-Up visits (up to a maximum of 780 days/18720 hours post dose).

Population: All enrolled participants treated who had at least 1 of the pharmacokinetic (PK) parameters of interest measured.

Maximum observed serum concentration (Cmax) of PF-06817024 following single dose in Part 1; Cmax was defined as the maximum observed serum concentration.

Outcome measures

Outcome measures
Measure	Part 1 Cohort 1: PF-06817024 10 mg IV SD n=5 Participants Healthy participants who might be mildly atopic received PF-06817024 10 mg IV for a SD on Study Day 1.	Part 1 Cohort 2: PF-06817024 30 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 30 mg SC SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 30 mg SC for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV SD n=3 Participants Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for a SD on Study Day 1.	Part 1 Cohort 3: PF-06817024 100 mg IV MD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 100 mg IV for MD (2 doses, on Study Days 1 and 31/46).	Part 1 Cohort 4: PF-06817024 300 mg IV SD n=6 Participants Healthy participants who might be mildly atopic received PF-06817024 300 mg IV for a SD on Study Day 1.	Part 1 Cohort 5: PF-06817024 1000 mg IV SD Healthy participants who might be mildly atopic received PF-06817024 1000 mg IV for a SD on Study Day 1.	Part 1: Placebo IV SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for a SD on Study Day 1.	Part 1 Cohort 3: Placebo IV MD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 IV for MD (2 doses, on Study Days 1 and 46/47).	Part 1 Cohort 7: Placebo SC SD Healthy participants who might be mildly atopic received the matching placebo of PF-06817024 SC for a SD on Study Day 1.
Maximum Observed Serum Concentration (Cmax) of PF-06817024 Following Single Dose in Part 1	2.879 ug/mL Geometric Coefficient of Variation 19	12.26 ug/mL Geometric Coefficient of Variation 20	2.471 ug/mL Geometric Coefficient of Variation 43	35.56 ug/mL Geometric Coefficient of Variation 11	97.49 ug/mL Geometric Coefficient of Variation 7	313.2 ug/mL Geometric Coefficient of Variation 17	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 1, 2, 4, 8, 12, 24, 48, 72, and 96 hr post dose on Day 1, Days 8 and 15, Day 31/46 (at pre-dose, 1, 2, 4, 8, 12, 24, 48 hr), Days 61, 91, 121, 151, 181, 211, 241, at Extended Follow-Up visits (up to a maximum of 645 days/15480 hr post dose).